OPKO Health, Inc. (NASDAQ:OPK – Get Rating) shares hit a new 52-week low during mid-day trading on Friday . The company traded as low as $1.02 and last traded at $1.03, with a volume of 629384 shares. The stock had previously closed at $1.12.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Friday.
OPKO Health Stock Down 5.4 %
The firm has a market capitalization of $819.05 million, a PE ratio of -2.41 and a beta of 1.68. The firm’s 50 day moving average price is $1.27 and its two-hundred day moving average price is $1.67. The company has a quick ratio of 1.28, a current ratio of 1.55 and a debt-to-equity ratio of 0.09.
OPKO Health (NASDAQ:OPK – Get Rating) last issued its earnings results on Thursday, February 23rd. The biotechnology company reported ($0.11) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.11). The company had revenue of $185.40 million for the quarter, compared to analysts’ expectations of $168.21 million. OPKO Health had a negative net margin of 32.70% and a negative return on equity of 15.55%. The firm’s revenue was down 53.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.11) earnings per share. As a group, research analysts forecast that OPKO Health, Inc. will post -0.33 EPS for the current fiscal year.
Insider Buying and Selling
In related news, major shareholder Opko Health, Inc. bought 14,285,714 shares of the firm’s stock in a transaction that occurred on Thursday, January 26th. The stock was purchased at an average price of $0.35 per share, for a total transaction of $4,999,999.90. Following the transaction, the insider now directly owns 94,285,714 shares of the company’s stock, valued at approximately $32,999,999.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 40.97% of the company’s stock.
Hedge Funds Weigh In On OPKO Health
A number of institutional investors and hedge funds have recently bought and sold shares of OPK. Envestnet Asset Management Inc. grew its position in OPKO Health by 29.1% in the 1st quarter. Envestnet Asset Management Inc. now owns 58,570 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 13,214 shares in the last quarter. Cetera Advisor Networks LLC boosted its position in shares of OPKO Health by 33.7% during the 1st quarter. Cetera Advisor Networks LLC now owns 15,156 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 3,820 shares in the last quarter. MetLife Investment Management LLC boosted its position in shares of OPKO Health by 70.6% during the 1st quarter. MetLife Investment Management LLC now owns 206,296 shares of the biotechnology company’s stock valued at $710,000 after purchasing an additional 85,349 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of OPKO Health by 73.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 7,184,414 shares of the biotechnology company’s stock valued at $24,717,000 after purchasing an additional 3,037,320 shares in the last quarter. Finally, Sequoia Financial Advisors LLC boosted its position in shares of OPKO Health by 11.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 94,071 shares of the biotechnology company’s stock valued at $324,000 after purchasing an additional 10,000 shares in the last quarter. Institutional investors own 23.49% of the company’s stock.
OPKO Health Company Profile
OPKO Health, Inc is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations.
Featured Articles
Receive News & Ratings for OPKO Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OPKO Health and related companies with MarketBeat.com’s FREE daily email newsletter.